Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL

Carcinogenesis

Volumn 32, Issue 10, 2011, Pages 1450-1458

  Kaminskyyy, Vitaliy O ^a   Surovay, Olga V ^a   Vaculova, Alena ^a   Zhivotovsky, Boris ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 8; CASPASE 9; COMPLEMENTARY DNA; CYTOCHROME C; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN BAX; PROTEIN BID; RNA 18S; TACEDINALINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; LUNG CANCER; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

AZACITIDINE; BLOTTING, WESTERN; CASPASE 8; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMALL CELL LUNG CARCINOMA; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 80053161379     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr135     Document Type: Article

References (39)

1. Johnson,B.E. et al. (1990) Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J. Clin. Oncol., 8, 396-401.
2. Lassen,U. et al. (1995) Long-term survival in small-cell lung cancer: post-treatment characteristics in patients surviving 5 to 18+ years-an analysis of 1,714 consecutive patients. J. Clin. Oncol., 13, 1215-1220.
3. Lawrence,D. et al. (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med., 7, 383-385.
4. Kischkel,F.C. et al. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity, 12, 611-620.
5. Yin,X.M. et al. (1999) Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature, 400, 886-891.
6. Joseph,B. et al. (1999) Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. Biochem. Biophys. Res. Commun., 262, 381-387.
7. Hopkins-Donaldson,S. et al. (2003) Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ., 10, 356-364.
8. Vaculova,A. et al. (2010) Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Mol. Cancer, 9, 87.
9. Fulda,S. et al. (2001) Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene, 20, 5865-5877.
10. Yang,X. et al. (2003) Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res., 63, 1122-1129.
11. Häcker,S. et al. (2009) Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene, 28, 3097-3110.
12. Shivapurkar,N. et al. (2002) Differential inactivation of caspase-8 in lung cancers. Cancer Biol. Ther., 1, 65-69.
13. Shivapurkar,N. et al. (2002) Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene, 21, 8510-8514.
14. Richon,V.M. et al. (2002) Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res., 8, 662-664.
15. Garcia-Manero,G. et al. (2006) Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood, 108, 3271-3279.
16. Walczak,H. et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 5, 157-163.
17. Wiley,S.R. et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-682.
18. Nakamura,M. et al. (2000) APO2L/TRAIL expression in human brain tumors. Acta Neuropathol., 99, 1-6.
19. Liu,S. et al. (2001) The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J. Immunol., 166, 5407-5415.
20. Belyanskaya,L.L. et al. (2008) TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer, 60, 355-365.
21. Cameron,E.E. et al. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet., 21, 103-107.
22. Suzuki,H. et al. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet., 31, 141-149.
23. Braiteh,F. et al. (2008) Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. Cancer Res., 14, 6296-6301.
24. Gray,S.G. et al. (2001) The human histone deacetylase family. Exp. Cell Res., 262, 75-83.
25. Göttlicher,M. et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 20, 6969-6978.
26. Krämer,O.H. et al. (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J., 22, 3411-3420.
27. Rountree,M.R. et al. (2000) DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet., 25, 269-277.
28. Ree,A.H. et al. (2008) HDAC2 deficiency and histone acetylation. Nat. Genet., 40, 812-813.
29. Zhang,X.D. et al. (2004) The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther., 3, 425-435.
30. Rosato,R.R. et al. (2003) Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther., 2, 1273-1284.
31. Singh,T.R. et al. (2005) HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene, 24, 4609-4623.
32. Insinga,A. et al. (2005) Inhibitors of histone deacetylases induce tumorselective apoptosis through activation of the death receptor pathway. Nat. Med., 11, 71-76.
33. Nebbioso,A. et al. (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med., 11, 77-84.
34. Fandy,T.E. et al. (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia, 7, 646-657.
35. Kim,Y.H. et al. (2004) Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis, 25, 1813-1820.
36. Butler,L.M. et al. (2006) The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int. J. Cancer, 119, 944-954.
37. Nakata,S. et al. (2004) Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene, 23, 6261-6271.
38. Guo,F. et al. (2004) Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res., 64, 2580-2589.
39. Jane,E.P. et al. (2011) Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol. Cancer Ther., 10, 198-208.